188582-62-9

Usage

Chemical Properties

white to light yellow crystalline powder or chunks

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 

Downstream Products

• 219873-06-0 3-fluoro-4-(hydroxymethyl)benzonitrile 
• 95068-02-3 4-bromo-2-fluoro-1-(methoxymethyl)benzene 
• 1418201-41-8 1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)-3-hydroxy-3-(trifluoromethyl)indolin-2-one 
• 1418201-42-9 1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)-3-hydroxy-3-(trifluoromethyl)indolin-2-one 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 1418201-57-6 1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)-1H-benzo[d][1,3]oxazin-2(4H)-one 
• 1418201-67-8 4-(4-hydroxymethyl-3-fluorophenyl)-1-methyl-1H-pyrazole 
• 1432436-23-1 N-(1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 1432436-20-8 N-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzylidene)-2-methylpropane-2-sulfinamide 
• 1183623-74-6 2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzaldehyde 
• 1432436-13-9 6-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1392081-37-6 4-(4-(chloromethyl)-3-fluorophenyl)-1-methyl-1H-pyrazole 
• 166960-01-6 4-bromo-2-fluoro-1-((2-methoxyethoxy)methyl)benzene 
• 942282-43-1 (4-bromo-2-fluorophenyl)methyl Methanesulfonate 

Relevant academic research and scientific papers

Liquid crystal compound

PROBLEM TO BE SOLVED: To provide a compound exhibiting high dissolubility in a liquid crystal composition and high storage stability, and a liquid crystal composition and a liquid crystal display element containing the compound as a constitutional member. SOLUTION: There are provided 4-ethoxy-4'-methoxymethyl-2,3,3'-trifluorobiphenyl capable of being synthesized for example by reduction of a formyl group from 2-fluoro-4-bromobenzaldehyde, etherification and coupling with an organic boron compound like a following formula, and 4-ethoxy-4'-methoxypropyl-2,3,3'-trifluorobiphenyl capable of being synthesized by a similar method. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE HAVING 18F ATOM INTRODUCED THEREINTO, AND PRECURSOR OF 4-BORONO-L-PHENYLALANINE HAVING 18F ATOM INTRODUCED THEREINTO

18F-labeled 4-boronophenylalanine (BPA) can be produced by preparing and further processing a precursor of 18F-labeled BPA represented by the following formula: in which R1 represents a bromo group, an iodo group, a fluoro group, a diazaborinane derivative, BX3? or BX3?M+ (wherein X represents a halogen atom; and M+ represents a monovalent monoatomic cation, a polyatomic cation or a complex cation).

SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II

The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted phenylureas and phenylamides of formula (I), to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

NOVEL ADENINE COMPOUND

An adenine compound useful for a medicament represented by the following formula (1): , wherein A1 and A2 are independently, optionally substituted cyclic aromatic hydrocarbon group or optionally substituted aromatic heterocyclic gro

NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula I, [Chemical formula should be inserted here. Please see paper copy] wherein R1 to R4 , R41 to R46 and Z have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias